<DOC>
	<DOCNO>NCT00796081</DOCNO>
	<brief_summary>The purpose study characterize pharmacokinetics paliperidone single- multiple-dose administration paliperidone ER child adolescent patient ( &gt; = 10 &lt; = 17 year age ) schizophrenia , schizoaffective disorder , schizophreniform disorder evaluate safety tolerability paliperidone ER patient population .</brief_summary>
	<brief_title>A Safety Pharmacokinetic Study ER OROS Paliperidone Pediatric Patients With Schizophrenia , Schizoaffective Disorder , Schizophreniform Disorder</brief_title>
	<detailed_description>The current study design multicenter , open-label , multiple-dose study child adolescent patient &gt; = 10 &lt; = 17 year age schizophrenia , schizoaffective disorder , schizophreniform disorder . The study include 3 dosage group ( 0.086 , 0.129 , 0.171 mg/kg/day paliperidone ER ) , study sequential ascend design , safety drug properly evaluate low dosage proceed next high dosage . The 3 dosage approximately 6 , 9 , 12 mg/day adult . Within dosage group , patient randomly assign 1 2 pharmacokinetic sampling schedule 1:1 ratio . For dosage group , study consist screen phase ( maximum 21 day ) ; 2-day , single-dose pharmacokinetic tolerability evaluation phase ; 7-day multiple-dose phase , evaluation pharmacokinetics tolerability ; end-of-study visit . Following completion patient give dosage group , sponsor evaluate safety tolerability treatment , order determine whether proceed next high low dosage level . The first group start 0.086 mg/kg/day . The hypothesis paliperidone ER well tolerate child adolescent patient schizophrenia , schizoaffective disorder , schizophreniform disorder , display expect pharmacokinetic characteristic population . Paliperidone ER 0.086 , 0.129 , 0.171 mg/kg/day , oral administration , single dose Day 1 study follow daily dosing Days 3 9 .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Patients ' height weight must within 5th 95th Physical Growth National Center Health Statistics percentiles age sex Patients must diagnosis schizophrenia subtype ( 295.10 295.20 295.30 295.60 295.90 ) , schizoaffective disorder ( 295.70 ) , schizophreniform disorder ( 295.40 ) , accord DSMIVTR Patients must healthy ( DSMIVTR classification ) , basis screen medical history , physical examination , 12lead ECG , clinical laboratory test ( hematology , serum chemistry , urinalysis ) . Patients laboratory result outside normal reference range include investigator , upon consultation sponsor , judge deviation clinically significant QT value must within normal limit patient must CGIS score less equal 3 Female patient must premenarchal , surgically sterile , abstinent , , sexually active , practice effective method birth control ( e.g. , prescription oral contraceptive , contraceptive injection , intrauterine device , doublebarrier method , contraceptive patch , male partner sterilization ) least 1 month study entry throughout study , negative serum betahuman chorionic gonadotropin pregnancy test screening , negative urine pregnancy test Day 1 Patients must sign informed assent document indicate understand purpose procedure require study willing participate study , Parent ( ) legal guardian ( ) patient signing informed consent document indicate understand purpose procedure require study give permission child 's participation study responsible person must available accompany patient investigational site visit Patients must agree hospitalized time study , parent ( ) legal guardian ( ) must consent , deem clinically necessary investigator . Patients active DSMIVTR axis I diagnosis schizophrenia , schizoaffective disorder , schizophreniform disorder Patients history DSMIVTR diagnosis substance dependence within 6 month screen ( nicotine caffeine dependence exclusionary ) patient involuntarily commit psychiatric hospitalization Patients significant risk suicidal violent ideation behavior , judge clinical investigator Female patient pregnant , plan become pregnant study , breastfeed Patients medical condition potentially alter absorption , metabolism , excretion study drug ( e.g. , Crohn 's disease , severe gastrointestinal narrowing [ pathologic iatrogenic ] , liver disease , renal disease ) Patients history malignancy , exception basal cell carcinoma , past 5 year Patients history positive result serology test ( e.g. , human immunodeficiency virus , hepatitis ) , history neuroleptic malignant syndrome</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective disorder</keyword>
	<keyword>Schizophreniform disorder</keyword>
	<keyword>Mood disorder</keyword>
	<keyword>Antipshychotic drug</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>ER OROS Paliperidone , Paliperidone ER</keyword>
</DOC>